Free Newsletter
Schering anesthesia med makes Euro-debut
Schering-Plough has launched its anesthesia-reversal drug Bridion in Sweden, with plans to inaugurate the drug in the U.K. and Germany soon. Known generically as sugammadex, the drug was rejected for U.S. sale by the FDA in August, on concerns about allergic reactions. The agency said it may ask for more data on those reactions. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: